{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-035600","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.409033+00:00","generated_at":"2026-06-09T04:37:56.419993+00:00","sec_items":["2.01","1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Avalo completes divestiture of AVTX-800 series for $150K upfront, up to $45M milestones","bullets":["Upfront payment of $150,000 from AUG; AUG assumed $150,000 of pre-closing liabilities.","Potential aggregate milestone payments of $45M ($15M per compound) upon first FDA approval for non-Rare Pediatric Disease.","AUG to share up to 20% of net proceeds from any future sale of priority review vouchers.","CEO states pipeline now focused on core immunology assets; transaction immediately improves cash flow."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-035600","json":"https://secwatch.observer/filing/0001628280-23-035600.json","markdown":"https://secwatch.observer/filing/0001628280-23-035600.md","text":"https://secwatch.observer/filing/0001628280-23-035600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023035600/0001628280-23-035600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023035600/avtx-20231027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:37:56.419993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"480235fd5e3fb9fab719e08c1d1bd761a741ad42","claim":"Avalo Therapeutics, Inc. completed a disposition involving AUG Therapeutics, LLC for $150,000 upfront plus contingent milestone payments (closed 2023-10-27).","evidence_excerpt":"previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement). AUG paid an upfront payment of $150,000, as well as, for each compound, is obligated to make a contingent milestone payment of $15,000,000 (for a potential aggregate of $45 million) if the first Food and Drug","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023035600/0001628280-23-035600-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"AUG Therapeutics, LLC"},{"label":"Consideration","value":"$150,000 upfront plus contingent milestone payments"},{"label":"Closing","value":"2023-10-27"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}